|Articles|February 7, 2019
Optimapharm acquires Swiss Denothex
Advertisement
Optimapharm, an independent clinical research organization (CRO), acquired Denothex Ltd. Optimapharm operates in offices across 14 European countries. It covers markets with a total population of over 500 million people, and conducts phase I – IV clinical research across Europe with a very strong footprint in Central and Eastern Europe.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
A Shot in the Arm to Traditional Vaccine Trial Strategy
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
5